Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferosym is a fixed-dose combination pharmaceutical product developed by Symphony Pharmaceuticals. It is composed of ferrous ascorbate, folic acid (vitamin B9), and zinc. Ferrous ascorbate serves as a highly bioavailable source of elemental iron, which is essential for the synthesis of hemoglobin and the prevention of iron-deficiency anemia. Folic acid is a critical cofactor in DNA synthesis and erythropoiesis, helping to prevent megaloblastic anemia and neural tube defects during pregnancy. Zinc is a trace mineral that supports immune function, protein synthesis, and various enzymatic processes. Ferosym is primarily indicated for the management of iron deficiency anemia and as a nutritional supplement during pregnancy and lactation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferrous ascorbate + folic acid + zinc (Symphony Pharmaceuticals).